secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001213900-24-020282
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX to acquire Adaptive Phage Therapeutics; raises $50M in PIPE
-----------------------------------------------------------------

- BiomX to issue 9.16M common shares, 40,471 Series X Preferred (convertible into 1,000 common each), and 2.17M warrants at $5.00 to APT stockholders.
- Concurrent $50M private placement via 216,417 Series X Preferred shares and 108.2M warrants at $231.10 per unit; RBC and Laidlaw acted as placement agents.
- Merger expects to close on first business day after conditions met, no earlier than March 12, 2024; lock-up agreements with directors, officers, and major stockholders.
- Support agreements secured covering majority of voting stockholders to vote in favor of conversion and other proposals at special meeting.
- Registration rights agreement requires filing resale registration statement within 45 days of PIPE closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024020282/0001213900-24-020282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024020282/ea0201229-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-020282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer